Evidence map›Paper›PMID 42577455›Full record

ArticleFrontiers in artificial intelligence2026

TriFusion-ADFormer: a deep learning framework for early Alzheimer's disease detection using MRI and cognitive metrics.

S Sabari Vasan, P Jayalakshmi

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

S Sabari VasanSchool of Computer Science Engineering and Information Systems, Vellore Institute of Technology, Vellore, India.
P JayalakshmiSchool of Computer Science Engineering and Information Systems, Vellore Institute of Technology, Vellore, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with the gradual loss of cognitive functions and neuronal degeneration. Early and accurate diagnosis is essential for timely therapeutic intervention and improved patient management. However, effectively integrating complementary multimodal information for reliable AD classification remains a significant challenge. Methods: This study proposes TriFusion-ADFormer, a multimodal deep learning framework for multiclass classification of Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal (CN) subjects. The framework extracts structural MRI features and MRI-derived clinical text summary based on volumetric measurements and cognitive assessment features such as MMSE, GDS, Global CDR, FAQ, and NPI-Q, then fuses them to classify the disease. Results: The proposed TriFusion-ADFormer achieved an overall classification accuracy of 86.0%, a Macro AUC of 0.93, and an F1-score of 86.0% for multiclass AD classification. Moreover, the MRI-based clinical summaries were also consistently consistent with structural abnormalities typically associated with AD, such as diffuse brain atrophy, which further supports the interpretability of the proposed framework. Discussion: The results show that the combination of multimodal information from structural MRI, semantic clinical summary generated from the MRI, and cognitive assessment scores enhances the accuracy and interpretability of Alzheimer's diagnosis. The results highlight the potential of incorporating complementary imaging, semantic, and cognitive features for better multiclass classification of AD, MCI, and CN in a transformer framework.

Indexed as

Alzheimer’s diseaseclinical data fusionMRI analysismultimodal deep learningSwin Transformer V2vision transformer

Identifiers

PMID42577455
PMCPMC13454240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.